Medigene and EpimAb Partner to Advance Off-the-Shelf TCR-TCE Therapies for Cancer

Medigene AG and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to research and dev...

February 27, 2025 | Thursday | News
Renovaro Biosciences and BioSymetrics Merge to Advance AI-Driven Precision Medicine

Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyon...

February 27, 2025 | Thursday | News
HBM Alpha Therapeutics Partners with Global Business Partner to Advance CRH-targeting Therapy for Endocrine Disorders

HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed, announced a strategic collaboration and license...

February 26, 2025 | Wednesday | News
Akeso Partner Summit Therapeutics Collaborates with Pfizer to Evaluate Ivonescimab in Combination with Pfizer’s ADCs in Solid Tumors

Akeso, Inc. ("Akeso" or the "Company") announced that its partner on ivonescimab, Summit Therapeutics Inc.  has entered into a clinical trial collabor...

February 25, 2025 | Tuesday | News
Incyte and Genesis Therapeutics Forge Strategic Collaboration to Accelerate Small Molecule Drug Discovery Using AI

Incyte  and Genesis Therapeutics, Inc. announced  that the companies have entered into a strategic collaboration focused on the researc...

February 21, 2025 | Friday | News
Spinal Cord Injury (SCI) Cases Expected to Rise by 2034, Highlighting the Need for Improved Treatments and Support

Spinal cord injury (SCI) is a sudden disruption of the spinal cord's neural tissue within the spinal canal, caused by trauma, disease, or degeneration. Thi...

February 20, 2025 | Thursday | News
Sanofi and Regeneron’s Dupixent Gains FDA Priority Review for Bullous Pemphigoid Treatment

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) t...

February 19, 2025 | Wednesday | News
Zoetis Receives USDA Conditional License for Avian Influenza Vaccine for Chickens

Zoetis announced that the U.S. Department of Agriculture (USDA), Center for Veterinary Biologics (CVB) has issued the company a conditional license for its...

February 17, 2025 | Monday | News
Kessler Foundation Achieves Breakthrough in Spinal Cord Injury Treatment with First Epidural Spinal Stimulator Implant

The Tim and Caroline Reynolds Center for Spinal Stimulation at Kessler Foundation is proud to announce the implantation of a spinal cord epidural stim...

February 12, 2025 | Wednesday | News
Novartis to Acquire Anthos Therapeutics, Advancing Development of Abelacimab for Stroke and Thrombosis Prevention

Novartis announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceut...

February 12, 2025 | Wednesday | News
BioMed X and Merck Reveal Critical Insights on Extrachromosomal DNA in Cancer Paving the Way for Novel Therapies

The research of BioMed X team EDC - Extrachromosomal DNA in Cancer - has uncovered critical insights into the mechanisms driving extrachromosomal ...

February 06, 2025 | Thursday | News
Partner Therapeutics Announces NEJM Publication of Phase 2 eNRGy Trial Results for Zenocutuzumab-Zbco (BIZENGRI®)

Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company announced  that the New England Journal of Medicine (NEJ...

February 06, 2025 | Thursday | News
Grifols Partners with FcR Therapeutics to Develop Nanobodies for Autoimmune Disease Treatment

Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines,  announced that it is col...

February 05, 2025 | Wednesday | News
Vanda Pharmaceuticals and AnaptysBio Enter Exclusive Global License Agreement for Imsidolimab in GPP Treatment

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) announced an exclusive, global license agreement ...

February 04, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close